Outcome of pediatric parameningeal rhabdomyosarcoma. The Children Cancer Hospital, Egypt, experience
Authors:
- Hany Abdel RahmanHRHany Abdel Rahman
- Mohamed SedkyMSMohamed Sedky
- Inas MohsenIMInas Mohsen
- Hala TahaHTHala Taha
- Iman LoayeILIman Loaye
- Mohamed S. ZaghloulMZMohamed S. Zaghloul
- Madiha El WakeelMWMadiha El Wakeel
- Rania M. LabibRLRania M. Labib
Open Access
- 1 June 2013
- journal article
- Published by Springer Nature in Journal of the Egyptian National Cancer Institute
- Vol. 25 (2) , 79-86
Abstract
PM RMS represents a diagnostic and therapeutic problem as it is less visible than other superficial head and neck sites, and has tendency to local and intracranial extension. The aim of this work is to study the treatment outcome, overall survival (OS) and event free survival (EFS) of pediatric PM RMS patients diagnosed and treated at the Children Cancer Hospital-Egypt [CCHE-57357] during a 4 year period. Retrospective review of charts of newly diagnosed pediatric PM RMS patients diagnosed and treated in CCHE during the period between July 2007 and the end of June 2011. Forty-two pediatric patients with PM RMS with age ranging from 3 months to 17.7 years (median 6.9 years) were studied. The follow up period ranged from 4 to 55 months with a median of 24.8 months. Twenty-one patients [50%] were stage III, while 11 patients [26.1%] were stage IV. The 3-year overall survival (OS) was 58.4 ± 8.9%. OS was 65.9 ± 10% for non metastatic tumors while it was 35.8 ± 16.2% for the metastatic ones (p=0.039). The 3-year event-free survival (EFS) was 48 ± 8.6% for the whole group. The non-metastatic and metastatic patients had 3-year EFS of 56.5 ± 9.7% and 24.9 ± 14.9% respectively. This difference was not statistically significant (p=0.127). PM RMS remains a diagnostic and therapeutic problem. Late presentation and advanced local disease compromise treatment options and decrease OS and EFS.Keywords
This publication has 29 references indexed in Scilit:
- Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II–IV, 1978–1997: Report from the Children's Oncology GroupPediatric Blood & Cancer, 2008
- Rhabdomyosarcoma of the Head and Neck Region: Experience at the Pediatric Unit of the Istituto Nazionale Tumori, MilanThe Journal of Otolaryngology, 2006
- Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcomaCancer, 2005
- Common Musculoskeletal Tumors of Childhood and AdolescenceNew England Journal of Medicine, 1999
- Childhood cancerCancer, 1995
- The intergroup rhabdomyosarcoma study-IICancer, 1993
- Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: A report from the international rhabdomyosarcoma workshopMedical and Pediatric Oncology, 1991
- The intergroup rhabdomyosarcoma study-I.A final reportCancer, 1988
- Improved prognosis with intensive treatment of children with cranial soft tissue sarcomas arising in nonorbital parameningeal sites. A report from the intergroup rhabdomyosarcoma studyCancer, 1987
- Incidence of meningeal involvement by rhabdomyosarcoma of the head and neck in children.A report of the intergroup rhabdomyosarcoma study (IRS)Cancer, 1978